Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Ocugen, Inc. (HSGX)
|
Add to portfolio |
|
|
|
| Price: |
$6.71
| | Metrics |
| OS: |
256.5
|
M
| |
-119
|
% ROE
|
| Market cap: |
$1.72
|
B
| |
-912
|
% ROIC
|
|
Net cash:
|
$67.8
|
M
| |
$0.26
|
per share
|
|
EV:
|
$1.65
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($88.1)
|
M
| |
|
|
|
EBIT
|
($88.8)
|
M
| |
|
|
| EPS |
($0.37)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-05-19 | Dec-31-18 | Dec-05-18 | Dec-31-17 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 8.1 | 0.0 | 10.3 | 0.0 |
| Revenue growth | | -100.0% | | | -21.7% | | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 14.2 | 0.0 | 16.1 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | -6.1 | 0.0 | -5.8 | 0.0 |
| Gross margin | | | 100.0% | | -75.2% | | -56.4% | |
| Selling, general and administrative | | | | | | | | |
| Research and development | 49.8 | 35.1 | 6.4 | 8.1 | | 10.3 | | 15.6 |
| General and administrative | 35.1 | 22.9 | 8.0 | 6.1 | 6.1 | 5.8 | 5.8 | 9.4 |
| EBIT | -84.9 | -58.0 | -14.3 | -14.2 | -14.2 | -16.1 | -16.1 | -25.0 |
| EBIT margin | | | -33220.9% | | -175.2% | | -156.4% | |
| Pre-tax income | -81.4 | -58.4 | -21.8 | -20.2 | -20.2 | -18.2 | -18.2 | -26.4 |
| Income taxes | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -81.4 | -58.4 | -34.4 | -20.2 | -20.2 | -18.2 | -18.2 | -22.5 |
| Net margin | | | -79925.6% | | -250.4% | | -176.5% | |
| |
| Diluted EPS | ($0.38) | ($0.30) | ($0.31) | ($1.46) | ($1.46) | ($3.67) | ($3.67) | ($0.99) |
| Shares outstanding (diluted) | 214.6 | 195.0 | 112.2 | 13.9 | 13.9 | 5.0 | 5.0 | 22.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|